Multiple Sclerosis — Global Competitive Landscape Report 2026

Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.

Executive Summary

Moreover, multiple sclerosis (MS) has one of the most mature disease-modifying therapy (DMT) franchises in modern neurology, with more than 20 approved agents across interferons, fumarates, S1P modulators, anti-CD20 monoclonal antibodies, and now — since 2025 — BTK inhibitors. The Patsnap Eureka pharma-intelligence stack returns 1,030 MS-tagged drug records, 5,351 MS-related patents filed since 2023, and 950 ongoing Phase 2/3 clinical trials.

Notably, the 2025 calendar year delivered two first-in-class BTK inhibitor approvals — Sanofi’s Tolebrutinib (2025-08-27) and Novartis’s Remibrutinib (2025-09-30) — opening a new oral-agent route for secondary progressive and relapsing forms, while Merck KGaA’s Evobrutinib failed its Phase 3 in 2023 defining the class’s early pharmacology risk. Among the 200 top-ranked MS drug records sampled from Eureka, the modality split is roughly 112 small molecules (56%), 26 monoclonal antibodies (13%), 9 autologous CAR-T cells (4.5%), 8 synthetic peptides, 5 interferons, and 5 mesenchymal stem cell therapies.

As a result, the competitive structure is now tiered: Roche/Genentech leads through the Ocrevus (ocrelizumab) anti-CD20 franchise — reinforced by a subcutaneous formulation approved 2024-06-24 — while Novartis and Sanofi enter a three-way BTK inhibitor race, and Biogen, BMS, TG Therapeutics, and J&J defend specific DMT mechanisms. A growing watchlist of autologous B-cell-depleting CAR-T programs from Cabaletta, Kyverna, and other cell-therapy developers signals a possible fourth treatment era: durable B-cell reset rather than continuous B-cell suppression.

---

Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below.

Arena Overview

Pipeline by Modality

Specifically, among 200 top-ranked MS-tagged drug records: 112 small molecules (S1P modulators, fumarates, BTK inhibitors, cladribine), 26 monoclonal antibodies (anti-CD20, anti-α4-integrin, anti-CD52), 9 autologous CAR-T candidates (emerging B-cell depletion paradigm), 8 synthetic peptides, 5 interferons (legacy first-line), 5 mesenchymal stem cell therapies, 4 diagnostic radiopharmaceuticals, 3 Fc fusion proteins, 2 immunoglobulins, and 2 gene therapies. Small molecules dominate because MS is now fundamentally an oral-agent market, especially after Gilenya’s 2010 launch reset physician expectations toward convenience.

Patent Filing Activity

Moreover, 5,351 MS-related patents were filed since January 2023 — one of the highest volumes across our tracked therapeutic areas, reflecting active IP fence-building around BTK inhibitor chemotypes, anti-CD20 next-generation formats, remyelination targets, and cell therapy vector designs. Active filers include Roche, Novartis, Sanofi, BMS, Biogen, Merck KGaA, InnoCare, Cabaletta Bio, Kyverna, and a growing roster of Chinese biotechs. 950 ongoing Phase 2/3 trials indicate that despite a crowded approved-drug landscape, clinical-stage exploration remains extensive — particularly for next-generation B-cell depletion, BTK inhibitor expansion into progressive MS, and remyelination agents.

Player Summary

Player	Region	Tier	Primary Route	Key Evidence
Roche / Genentech	CH/US	T1 (Leader)	Anti-CD20 mAb (ocrelizumab)	Ocrevus approved 2017-03-28; subcutaneous formulation (ocrelizumab/hyaluronidase) approved 2024-06-24; PPMS + RRMS franchise leader
Novartis	CH	T1 (Challenger)	Anti-CD20 mAb + BTK inhibitor + S1P	Kesimpta (ofatumumab, 2020); Remibrutinib BTK inhibitor approved 2025-09-30; Gilenya (fingolimod, 2010) + Mayzent (siponimod, 2019)
Sanofi	FR	T1 (Challenger)	BTK inhibitor + anti-CD52	Tolebrutinib BTK inhibitor approved 2025-08-27 (first-in-class for secondary progressive); Lemtrada (alemtuzumab, anti-CD52); Aubagio (teriflunomide)
Biogen	US	T2 (Challenger)	Anti-α4-integrin + fumarates + anti-CD20	Tysabri (natalizumab); Tecfidera (dimethyl fumarate); Vumerity (diroximel fumarate); Rituxan (co-market)
Bristol Myers Squibb	US	T2 (Challenger)	S1P modulator	Zeposia (ozanimod, 2020); oral S1P with cardiac safety differentiation vs. fingolimod
TG Therapeutics	US	T2 (Challenger)	Anti-CD20 mAb	Briumvi (ublituximab, 2022-12-28); glycoengineered anti-CD20 with shorter infusion time than Ocrevus
Johnson & Johnson	US	T2 (Challenger)	S1P modulator	Ponvory (ponesimod, 2021-03-18); selective S1P1 for optimized cardiac/immunology profile
Merck KGaA	DE	T2 (Challenger)	Cladribine + BTK (failed)	Mavenclad (cladribine) oral pulse therapy; Evobrutinib Phase 3 failure (2023) — class cautionary signal
Horizon / Amgen	IE/US	T3 (Follower, Niche)	Anti-CD19 mAb (NMOSD primary, MS investigational)	Uplizna (inebilizumab, 2020-06-11); primary indication NMOSD; MS cross-evaluated
InnoCare Pharma	CN	T3 (Follower)	BTK inhibitor	Orelabrutinib (2020-12-25, initial hematology indication); investigated in MS and other autoimmune diseases
Cabaletta Bio	US	Watchlist (Emerging)	Autologous CAR-T (anti-CD19 / anti-CD20)	CABA-201 autoimmune CAR-T platform; MS investigational readouts expected 2026+
Kyverna Therapeutics	US	Watchlist (Emerging)	Autologous CAR-T	KYV-101 CAR-T in myasthenia gravis and MS; autoimmune B-cell reset paradigm
Contineum Therapeutics	US	Watchlist (Remyelination)	Remyelination small molecule	PIPE-307 M1R antagonist for oligodendrocyte differentiation; disease-modifying progressive MS target
Clene Nanomedicine	US	Watchlist (Remyelination)	Gold nanocrystal CSF-penetrant	CNM-Au8 investigated for neuronal energetic rescue and remyelination
Nexocell Therapeutics	CN/US	Watchlist	CAR-T for autoimmune disease	Anti-CD19/CD20 autologous CAR-T; China-region MS expansion

---

Route Differentiation Analysis

In particular, six distinct mechanism classes define the current MS treatment stack:

Player	Anti-CD20 mAb	BTK Inhibitor	S1P Modulator	Fumarate	α4-integrin / Other mAb	B-cell CAR-T / Remyelination
Roche / Genentech	Strong — Ocrevus IV + SC 2024	Absent	Absent	Absent	Absent	Absent
Novartis	Strong — Kesimpta (SC)	Strong — Remibrutinib 2025-09	Strong — Gilenya + Mayzent	Absent	Absent	Absent
Sanofi	Absent	Strong — Tolebrutinib 2025-08	Absent	Absent	Strong — Lemtrada (anti-CD52), Aubagio	Absent
Biogen	Moderate — Rituxan co-market	Absent	Absent	Strong — Tecfidera, Vumerity	Strong — Tysabri (α4)	Absent
BMS	Absent	Absent	Strong — Zeposia	Absent	Absent	Absent
TG Therapeutics	Strong — Briumvi (glycoengineered)	Absent	Absent	Absent	Absent	Absent
Johnson & Johnson	Absent	Absent	Strong — Ponvory	Absent	Absent	Absent
Merck KGaA	Absent	Failed — Evobrutinib P3	Absent	Absent	Absent	Moderate — Mavenclad (cladribine pulse)
Horizon / Amgen	Moderate — Uplizna (anti-CD19)	Absent	Absent	Absent	Absent	Absent
InnoCare	Absent	Moderate — Orelabrutinib investigational	Absent	Absent	Absent	Absent
Cabaletta Bio	Absent	Absent	Absent	Absent	Absent	Strong — CABA-201 CAR-T
Kyverna	Absent	Absent	Absent	Absent	Absent	Strong — KYV-101 CAR-T
Contineum	Absent	Absent	Absent	Absent	Absent	Strong — PIPE-307 remyelination
Clene	Absent	Absent	Absent	Absent	Absent	Emerging — CNM-Au8

Route Concentration Observations

• Additionally, Anti-CD20 is the high-efficacy standard of care: Additionally, Ocrevus, Kesimpta, Briumvi, and Rituxan (off-label) collectively anchor relapsing MS treatment. Subcutaneous formulations (Kesimpta SC, Ocrevus SC from 2024) shift the competitive axis from efficacy toward delivery convenience.
• Meanwhile, BTK inhibitors are the newest wave and most contested route: Meanwhile, Sanofi’s Tolebrutinib and Novartis’s Remibrutinib both reached approval in Q3 2025, with Merck KGaA’s Evobrutinib as a 2023 failure case. The mechanism targets CNS-penetrant B-cell and microglial BTK signaling — potentially addressing progressive disease where anti-CD20 has been less effective.
• In contrast, S1P modulators occupy an oral maintenance tier: In contrast, Gilenya (fingolimod), Mayzent (siponimod), Zeposia (ozanimod), and Ponvory (ponesimod) differentiate by receptor selectivity and cardiac / hepatic safety profiles. Generic fingolimod entry has compressed pricing pressure.
• Similarly, Fumarates defend a convenience niche: Similarly, Tecfidera (dimethyl fumarate), Vumerity (diroximel fumarate), Bafiertam (monomethyl fumarate), and 2025 approval Tegomil fumarate compete on tolerability / GI side effect profile within the oral-DMT segment.
• Furthermore, Autoimmune CAR-T is the watchlist signal: Furthermore, Cabaletta (CABA-201), Kyverna (KYV-101), and Nexocell are developing autologous CD19/CD20 CAR-T for autoimmune diseases including MS. Early readouts in other B-cell-driven autoimmune conditions suggest a durable “B-cell reset” paradigm rather than continuous suppression.
• Notably, Remyelination remains a white space: Notably, despite decades of academic interest, only a handful of clinical-stage remyelination agents exist (Contineum PIPE-307, Clene CNM-Au8). Evidence of genuine remyelination in humans has been elusive.

---

Top Player Deep Dives

1. Roche / Genentech (Tier 1 — Leader)

Primary route: However, anti-CD20 monoclonal antibody (ocrelizumab) delivered IV originally and via subcutaneous injection since 2024.

Key approved products: Specifically, Ocrevus (ocrelizumab, IV) approved 2017-03-28 for relapsing MS and primary progressive MS; Ocrevus/hyaluronidase-ocsq (SC formulation) approved 2024-06-24, cutting administration time from hours to ~10 minutes.

Differentiation: Notably, Ocrevus was the first drug with a primary progressive MS indication; the SC formulation converts an infusion-center drug into a clinic-office drug, defending share against Kesimpta’s subcutaneous advantage.

Trajectory: Moreover, as anti-CD20 has become the high-efficacy standard, Roche’s strategic focus has shifted to defending against biosimilar entry, expanding into pediatric and earlier-line settings, and adding differentiating formulations.

Key risk: However, Ocrevus reaches initial biosimilar horizon in the late 2020s; BTK inhibitors in progressive MS could erode the unique PPMS positioning if they show durable benefit.

2. Novartis (Tier 1 — Triple-Modality Challenger)

Primary route: In addition, portfolio spanning anti-CD20, BTK inhibitor, and S1P modulators — the broadest MS franchise by mechanism breadth.

Key approved products: Specifically, Kesimpta (ofatumumab SC, 2020); Remibrutinib (BTK inhibitor, approved 2025-09-30); Gilenya (fingolimod, 2010); Mayzent (siponimod, 2019) for secondary progressive MS; Extavia (interferon beta-1b, legacy).

Differentiation: Notably, Novartis is the only major with both an anti-CD20 subcutaneous product (Kesimpta) and a 2025 BTK inhibitor approval, allowing sequencing and combination strategies across MS disease stages.

Trajectory: Moreover, Novartis’s 2025 BTK entry allows direct competition with Sanofi’s Tolebrutinib while preserving leadership in oral S1P chemistry through ongoing label expansions.

Key risk: However, fingolimod has faced patent expiry and generic pressure; Remibrutinib’s long-term safety profile is still maturing, with Evobrutinib’s Phase 3 failure serving as a class-wide cautionary reference.

3. Sanofi (Tier 1 — BTK Inhibitor Frontrunner for Progressive MS)

Primary route: As a result, BTK inhibitor (Tolebrutinib) for progressive MS + anti-CD52 (alemtuzumab / Lemtrada) for severe relapsing MS + DHODH inhibitor (teriflunomide / Aubagio) oral.

Key approved products: Specifically, Tolebrutinib (approved 2025-08-27) — the first BTK inhibitor to achieve a regulatory milestone for secondary progressive MS; Lemtrada (alemtuzumab); Aubagio (teriflunomide, 2012); legacy Copaxone and MS Serono interferon lineage partially inherited via corporate restructuring.

Differentiation: Notably, Tolebrutinib’s CNS penetration and its positioning in progressive MS (where anti-CD20 efficacy is limited) defines its commercial thesis; Lemtrada remains a unique induction-style option despite its complex safety monitoring.

Trajectory: Moreover, Tolebrutinib’s approval positions Sanofi as the progressive MS BTK leader; label expansions into primary progressive MS and earlier-line relapsing MS are the key 2026–2027 readouts.

Key risk: However, BTK inhibitor long-term safety (hepatic and cardiovascular) is still accumulating; Lemtrada’s REMS complexity limits uptake relative to Ocrevus.

4. Biogen (Tier 2 — Established Multi-Mechanism Challenger)

Primary route: Specifically, portfolio across anti-α4-integrin (natalizumab), fumarates (dimethyl / diroximel / monomethyl), anti-CD20 co-marketing (Rituxan), plus legacy interferon franchise.

Key approved products: Specifically, Tysabri (natalizumab, 2004); Tecfidera (dimethyl fumarate, 2013) — flagship oral MS franchise that faced generic entry post-2020; Vumerity (diroximel fumarate, 2019); Plegridy (peginterferon beta-1a, 2014); Rituxan co-marketing.

Differentiation: Notably, Biogen’s franchise depth spans high-efficacy (Tysabri) and oral convenience (fumarates), positioning it as a full-stack DMT player across severity tiers.

Trajectory: Moreover, Tecfidera’s generic erosion has prompted a pipeline pivot toward next-generation mechanisms; Biogen has publicly deprioritized some earlier MS programs to focus on Alzheimer’s and rare neurology.

Key risk: However, Tysabri PML risk continues to limit frontline use; the absence of a proprietary high-efficacy anti-CD20 or BTK agent weakens Biogen’s position vs. Roche, Novartis, and Sanofi.

5. TG Therapeutics (Tier 2 — Anti-CD20 Differentiator)

Primary route: Meanwhile, glycoengineered anti-CD20 monoclonal antibody (ublituximab) with faster infusion time than Ocrevus.

Key approved product: Specifically, Briumvi (ublituximab-xiiy) approved 2022-12-28; ULTIMATE I and II pivotal trials demonstrated non-inferiority vs. teriflunomide.

Differentiation: Notably, Briumvi’s 1-hour infusion time (vs. Ocrevus’s multi-hour initial infusion) addresses infusion-chair capacity constraints; low glycoengineered CD20 affinity is designed for enhanced ADCC.

Trajectory: Moreover, uptake since launch has been modest vs. Ocrevus’s established franchise; competitive dynamics favor TG in capacity-constrained infusion centers.

Key risk: However, single-asset dependency in MS limits diversification; entering the anti-CD20 market late with no PPMS label restricts growth.

6. Cabaletta Bio / Kyverna (Watchlist — Autoimmune CAR-T)

Primary route: In contrast, autologous CD19 (Kyverna) or CD19/BCMA (Cabaletta) CAR-T for durable B-cell reset in autoimmune disease, including MS.

Key pipeline: Specifically, Kyverna KYV-101 (CD19 CAR-T) in myasthenia gravis, progressive MS, systemic sclerosis; Cabaletta CABA-201 CAAR-T / CAR-T platform; multiple academic collaborations extending lupus CAR-T data into MS.

Differentiation: Notably, one-time administration with multi-year B-cell reset creates a fundamentally different treatment paradigm from continuous anti-CD20 or BTK dosing; potentially disease-modifying rather than suppressive.

Trajectory: Moreover, early Phase 1/2 readouts in other B-cell-driven autoimmune conditions (lupus, myasthenia) have shown durable remission signals; MS-specific data readouts expected 2026+.

Key risk: However, CAR-T cost, conditioning chemotherapy, and logistics create major payer-access barriers in a therapeutic area with mature, convenient oral and subcutaneous alternatives.

---

BD Deals & Strategic Moves

Deal Timeline

Similarly, key business development activity shaping the MS competitive landscape:

Date	Deal / Event	Parties	Type	Significance
2017-03	Ocrevus FDA approval	Roche / Genentech / FDA	Regulatory	First anti-CD20 for relapsing MS + first PPMS indication; market-reshaping launch
2020-08	Kesimpta FDA approval	Novartis	Regulatory	First subcutaneous anti-CD20 for MS; positions Novartis for convenience-oriented competition
2022-12	Briumvi FDA approval	TG Therapeutics	Regulatory	Glycoengineered anti-CD20 with faster infusion; third commercial anti-CD20 in MS
2023	Evobrutinib Phase 3 failure	Merck KGaA	Clinical failure	First BTK inhibitor Phase 3 miss in MS; class safety scrutiny intensified (hepatic findings)
2024-06	Ocrevus SC (ocrelizumab/hyaluronidase) FDA approval	Roche	Regulatory	Subcutaneous IV alternative; defends Ocrevus franchise vs. Kesimpta convenience
2024-11	Obecabatagene autoleucel approval (non-MS, signal-relevant)	Autolus	Regulatory (adjacent)	Autologous CD19 CAR-T hematology precedent reinforces feasibility for autoimmune CAR-T
2025-08	Tolebrutinib approval	Sanofi	Regulatory	First BTK inhibitor approved for MS; secondary progressive MS indication
2025-09	Remibrutinib approval	Novartis	Regulatory	Second BTK inhibitor in MS; opens oral BTK class competition
2023+	Autoimmune CAR-T platform emergence	Kyverna, Cabaletta, Nexocell and others	Pipeline expansion	CD19/CD20 CAR-T extending from lupus and myasthenia to MS investigational protocols
Ongoing	Ocrevus biosimilar preparation	Multiple biosimilar developers	Biosimilar IP	Anti-CD20 biosimilar entry expected late 2020s; pricing pressure across the class

Strategic Pattern

Overall, the MS BD landscape has shifted from consolidation-era M&A (Ocrevus launch, fumarate rollouts) toward a defense-and-expand pattern: incumbents protect established franchises through formulation innovation (Ocrevus SC, Kesimpta SC), and the 2025 BTK inhibitor wave from Sanofi and Novartis establishes the first new oral DMT route in a decade. M&A activity is thin because the incumbent franchises are already well-capitalized; most innovation now comes from specialist biotechs (TG Therapeutics, Cabaletta, Kyverna, Contineum) entering via clinical differentiation rather than corporate transactions.

---

Unmet Needs & White Spaces

Opportunity Matrix

Notably, three white spaces meet all three criteria — sparse coverage, clear technical value, and a realistic entry path:

White Space	Current Coverage	Technical Value	Entry Path
Remyelination and neuroprotection	Sparse — Contineum PIPE-307 (M1R antagonist), Clene CNM-Au8 are the only Phase 2/3-stage assets; decades of academic failures	High — addresses progressive disability accumulation independent of immune suppression; currently no approved drug	Oligodendrocyte-differentiating small molecules, anti-LINGO biologics, or CNS-penetrant growth-factor mimetics; target-stratified progressive MS populations
Durable B-cell reset via one-time CAR-T	Emerging — Cabaletta, Kyverna, Nexocell in Phase 1/2; very few China-region programs	High — one-time treatment paradigm vs. continuous anti-CD20 dosing; potentially disease-modifying rather than suppressive	Autologous CAR-T with autoimmune-optimized conditioning, improved safety profile, lower manufacturing cost; or allogeneic / in-vivo CAR-T to reduce access barriers
Progressive MS disease-modifying therapy	Moderate — Ocrevus (PPMS label), Mayzent (SPMS label), Tolebrutinib (SPMS label 2025); all provide modest effect sizes	High — >50% of MS patients eventually progress; current options slow but do not halt progression	Combinations of immune and neuroprotective mechanisms; CNS-penetrant novel targets (NMDAR, kainate, microglial regulators) beyond BTK

---

Risks and Strategic Outlook for 2026 and Beyond

Key Risks

1. Additionally, BTK inhibitor long-term safety: the Evobrutinib Phase 3 failure and subsequent hepatic-safety findings have created a class-wide trust overhang. Tolebrutinib and Remibrutinib enter the market with intensive post-approval safety surveillance; a significant safety signal could compress class uptake.
2. Meanwhile, Biosimilar pressure on anti-CD20 franchises: Ocrevus biosimilar horizon approaches in the late 2020s; Kesimpta faces parallel pricing pressure. Franchise revenues across the category will compress even as prescribing volume grows.
3. In contrast, CAR-T access and reimbursement: even if autoimmune CAR-T demonstrates durable B-cell reset in MS, per-patient costs of $400K+ and conditioning chemotherapy create real-world access friction in a disease with convenient oral alternatives. In-vivo CAR-T or allogeneic formats may be required to unlock this paradigm.
4. Similarly, Patent fence density: 5,351 MS-related patents filed since 2023 indicate one of the most active fence-building landscapes in our tracked categories. Freedom-to-operate analyses for new entrants on BTK chemotypes, anti-CD20 glycoengineering, and CAR-T vector designs are increasingly non-trivial.

Strategic Outlook

Furthermore, for strategic planning: the safest near-term bets in MS are subcutaneous-formulation extensions of established anti-CD20 mAbs (Ocrevus SC, Kesimpta SC) and second-generation BTK inhibitor label expansions (Tolebrutinib PPMS, Remibrutinib RRMS) where mechanism and clinical infrastructure are established. However, the highest-upside, highest-risk bets are in autoimmune CAR-T with durable B-cell reset, remyelination agents with biomarker-validated endpoints, and combination regimens targeting both the immune and neurodegenerative components of progressive MS. The watchlist signal is on whether Cabaletta or Kyverna can produce a durable-remission Phase 2 readout in MS specifically — such data would reframe the treatment paradigm from “suppression” to “reset.”

If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.